We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+18.23%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$158M
Cap. Flow
+$36.7M
Cap. Flow %
2.84%
Top 10 Hldgs %
39.6%
Holding
109
New
17
Increased
24
Reduced
36
Closed
22

Top Buys

Rank Stock Value
1
GRFS
Grifois
GRFS
+$36.8M
2
SNY icon
Sanofi
SNY
+$29.7M
3
QDEL icon
QuidelOrtho
QDEL
+$27.8M
4
KRYS icon
Krystal Biotech
KRYS
+$17.5M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$24.3M
2
NRIX icon
Nurix Therapeutics
NRIX
+$22.4M
3
PEN icon
Penumbra
PEN
+$22.2M
4
HUM icon
Humana
HUM
+$16.6M
5
GSK icon
GSK
GSK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
26
Eli Lilly
LLY
$1.03T
$17.1M 1.32%
+19,300
New +$17.4M
NPCE icon
27
Neuropace
NPCE
$458M
$17M 1.31%
2,433,168
– –
EOLS icon
28
Evolus
EOLS
$404M
$16.8M 1.3%
1,037,680
-114,320
-10% -$1.6M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$30.5B
$16.3M 1.27%
59,400
-12,300
-17% -$3.2M
ANIP icon
30
ANI Pharmaceuticals
ANIP
$1.82B
$16M 1.24%
+269,000
New +$16.4M
ELV icon
31
Elevance Health
ELV
$85B
$15.4M 1.19%
+29,650
New +$15.8M
RIGL icon
32
Rigel Pharmaceuticals
RIGL
$726M
$15.1M 1.17%
934,788
-108,909
-10% -$1.28M
PRAX icon
33
Praxis Precision Medicines
PRAX
$8.81B
$14.9M 1.16%
259,398
-273,617
-51% -$14.8M
KROS icon
34
Keros Therapeutics
KROS
$198M
$13M 1.01%
224,600
+3,000
+1% +$148K
CGON icon
35
CG Oncology
CGON
$6.38B
$12.9M 1%
340,585
-84,000
-20% -$2.94M
IMUX icon
36
Immunic
IMUX
$189M
$12M 0.93%
729,301
– –
BHC icon
37
Bausch Health
BHC
$2.32B
$11.6M 0.9%
1,424,000
+218,000
+18% +$1.44M
PHVS icon
38
Pharvaris
PHVS
$2.34B
$11.1M 0.86%
598,169
+198,739
+50% +$3.63M
LBPH
39
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$10.6M 0.82%
+318,269
New +$11M
OFIX icon
40
Orthofix Medical
OFIX
$425M
$9.48M 0.73%
606,933
+555,933
+1,090% +$8.91M
VSTM icon
41
Verastem
VSTM
$516M
$8.46M 0.65%
2,827,963
+1,166,666
+70% +$3.17M
ENTA icon
42
Enanta Pharmaceuticals
ENTA
$388M
$8.14M 0.63%
785,546
-14,000
-2% -$183K
KIDS icon
43
OrthoPediatrics
KIDS
$553M
$7.83M 0.61%
288,945
-20,555
-7% -$623K
ACLX
44
DELISTED
Arcellx
ACLX
$7.77M 0.6%
93,031
-77,710
-46% -$5.17M
NUVL
45
DELISTED
Nuvalent
NUVL
$7.61M 0.59%
74,357
-97,431
-57% -$8.08M
KNSA icon
46
Kiniksa Pharmaceuticals
KNSA
$6.04B
$7.56M 0.59%
302,500
+102,500
+51% +$2.5M
BDSX icon
47
Biodesix
BDSX
$237M
$7.19M 0.56%
201,903
-103,695
-34% -$3.57M
TAK icon
48
Takeda Pharmaceutical
TAK
$53B
$7.11M 0.55%
+500,000
New +$7.09M
RLAY icon
49
Relay Therapeutics
RLAY
$4.27B
$6.44M 0.5%
+910,000
New +$6.8M
SMMT icon
50
Summit Therapeutics
SMMT
$10.8B
$6.24M 0.48%
+285,000
New +$3.99M
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Soleus Capital Management held 109 positions worth $1.29B, up 14% from $1.13B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Soleus Capital Management's Q3 2024 filing shows 17 new, 24 increased, 36 reduced and 22 closed positions. Its largest new stake was Grifois: 4,521,703 shares worth $40.2M. The largest sale was TG Therapeutics, an estimated $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

  • Soleus Capital Management's largest Q3 2024 buy was Grifois: 4,521,703 shares worth $40.2M.
  • Soleus Capital Management added most to Sanofi in Q3 2024, an estimated $29.7M increase.
  • Soleus Capital Management's biggest Q3 2024 reduction was TG Therapeutics, cutting an estimated $24.3M.
  • Soleus Capital Management fully exited Penumbra in Q3 2024, selling an estimated $22.2M.
  • Soleus Capital Management's ten largest holdings make up 40% of its $1.29B portfolio in Q3 2024.
  • Soleus Capital Management opened 17 new positions and closed 22 in Q3 2024.
  • Soleus Capital Management's portfolio value rose 14% quarter-over-quarter to $1.29B.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.